{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:13:46Z","timestamp":1790108026787,"version":"4.0.1"},"reference-count":51,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-115176"],"award-info":[{"award-number":["TSGH-D-115176"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,17]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 messenger RNA (mRNA) vaccines enhance immune checkpoint inhibitor (ICI) efficacy through type I interferon responses, but may theoretically increase the burden of immune-related adverse events (irAEs). This study aimed to determine whether vaccination increases irAE risk in patients with ICI-treated cancer and to quantify the balance between toxicity and survival benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using target trial emulation methodology within the TriNetX Research Global Network (January 2021 to December 2025). We identified 7,218 adult patients with metastatic cancer initiating ICI therapy. Patients who received COVID-19 mRNA vaccination within 100 days before ICI initiation (n=3,609) were matched 1:1 to unvaccinated controls (n=3,609) using propensity scores. The primary outcome was the composite incidence of irAEs at 36 months. Secondary outcomes included severe irAEs, organ-specific irAEs, all-cause mortality, and intensive care unit (ICU) admission. Probabilistic quantitative bias analysis (VanderWeele-Ding formulation) and a composite ocular negative-control outcome (incident age-related cataract and glaucoma) were used to assess robustness to unmeasured confounding and differential ophthalmological surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Vaccinated patients had a significantly increased risk of overall irAEs compared with unvaccinated controls (HR 1.22, 95% CI 1.17 to 1.28; E-value 1.74). This increase included clinically significant severe irAEs (HR 1.11, 95% CI 1.04 to 1.18). Organ-specific analyses revealed that the overall increase was primarily driven by ocular irAEs (HR 1.48, 95% CI 1.17 to 1.87), with non-significant trends for dermatologic and rheumatologic irAEs. However, vaccination was associated with substantial survival benefits, including 14% lower all-cause mortality (HR 0.86, 95% CI 0.80 to 0.93) and 57% fewer ICU admissions (HR 0.43, 95% CI 0.25 to 0.73). Point estimates were numerically higher in females and patients aged \u226550 years, although tests for interaction were not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>COVID-19 mRNA vaccination is associated with a modest but clinically meaningful 22% increase in irAEs, driven largely by ocular manifestations. However, the substantial survival benefits clearly outweigh these toxicity risks. Vaccination should continue in all eligible patients, with enhanced monitoring recommended for irAEs, particularly ophthalmological surveillance for high-risk groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014726","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:25:23Z","timestamp":1782397523000},"page":"e014726","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 mRNA vaccination and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a target trial emulation study"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-6417","authenticated-orcid":false,"given":"Po-Huang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Cheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universal Eye Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[{"name":"Neurological Institute, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical University, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical University, Taipei, Taiwan"},{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Yi-Jin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-5168","authenticated-orcid":false,"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026062507251508000_14.6.e014726.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026062507251508000_14.6.e014726.2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"2026062507251508000_14.6.e014726.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7"},{"key":"2026062507251508000_14.6.e014726.4","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2022.7048","article-title":"Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade","volume":"20","author":"Widman","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026062507251508000_14.6.e014726.5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00155-8"},{"key":"2026062507251508000_14.6.e014726.6","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026062507251508000_14.6.e014726.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2026062507251508000_14.6.e014726.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"2026062507251508000_14.6.e014726.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071108","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"2026062507251508000_14.6.e014726.10","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"2026062507251508000_14.6.e014726.11","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"2026062507251508000_14.6.e014726.12","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"2026062507251508000_14.6.e014726.13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu149"},{"key":"2026062507251508000_14.6.e014726.14","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2026062507251508000_14.6.e014726.15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"JAMA Oncology Patient Page. Performance Status in Patients With Cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026062507251508000_14.6.e014726.16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/cer-2017-0040","article-title":"Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups","volume":"7","author":"Sheffield","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2026062507251508000_14.6.e014726.17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7501"},{"key":"2026062507251508000_14.6.e014726.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.09.017"},{"key":"2026062507251508000_14.6.e014726.19","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4264"},{"key":"2026062507251508000_14.6.e014726.20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/09273948.2021.1976221","article-title":"Ocular Adverse Events After COVID-19 Vaccination","volume":"29","author":"Ng","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"2026062507251508000_14.6.e014726.21","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.nerep.2022.100121","article-title":"Optic neuropathy after COVID-19 vaccination: case report and systematic review","volume":"2","author":"Haseeb","year":"2022","journal-title":"Neuroimmunol Rep"},{"key":"2026062507251508000_14.6.e014726.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.006"},{"key":"2026062507251508000_14.6.e014726.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006246","article-title":"COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Ruiz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026062507251508000_14.6.e014726.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00487"},{"key":"2026062507251508000_14.6.e014726.25","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7109a2"},{"key":"2026062507251508000_14.6.e014726.26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2025.2020","article-title":"COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults With Cancer","volume":"11","author":"Skarbinski","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026062507251508000_14.6.e014726.27","unstructured":"Centers for Disease Control and Prevention . COVIDVaxView weekly COVID-19 vaccination dashboard. Atlanta, GA: CDC, 2026. Available: https:\/\/www.cdc.gov\/covidvaxview\/weekly-dashboard\/"},{"key":"2026062507251508000_14.6.e014726.28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.15585\/mmwr.mm7346a1","article-title":"Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2024","volume":"73","author":"Kriss","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026062507251508000_14.6.e014726.29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153883","article-title":"Cancer Patients\u2019 Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea","volume":"13","author":"Chun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062507251508000_14.6.e014726.30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.japh.2018.09.007","article-title":"Comparisons of immunization records between a community pharmacy, a regional registry, and a health system","volume":"59","author":"Lam","year":"2019","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2026062507251508000_14.6.e014726.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"2026062507251508000_14.6.e014726.32","doi-asserted-by":"publisher","DOI":"10.1038\/nature18300"},{"key":"2026062507251508000_14.6.e014726.33","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13443"},{"key":"2026062507251508000_14.6.e014726.34","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050435","article-title":"Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2026062507251508000_14.6.e014726.35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaophthalmol.2024.0973","article-title":"COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis","volume":"142","author":"Kim","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026062507251508000_14.6.e014726.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.07.017"},{"key":"2026062507251508000_14.6.e014726.37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ajo.2024.01.038","article-title":"Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study","volume":"262","author":"Kim","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"2026062507251508000_14.6.e014726.38","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1080\/09273948.2023.2200858","article-title":"COVID Vaccine-Associated Uveitis","volume":"31","author":"Habot-Wilner","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"2026062507251508000_14.6.e014726.39","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2008.27"},{"key":"2026062507251508000_14.6.e014726.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00037","article-title":"Ocular Immune Privilege and Transplantation","volume":"7","author":"Taylor","year":"2016","journal-title":"Front Immunol"},{"key":"2026062507251508000_14.6.e014726.41","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1102574"},{"key":"2026062507251508000_14.6.e014726.42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42440"},{"key":"2026062507251508000_14.6.e014726.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026062507251508000_14.6.e014726.44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062507251508000_14.6.e014726.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026062507251508000_14.6.e014726.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026062507251508000_14.6.e014726.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062507251508000_14.6.e014726.48","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/rheumatology\/keab486","article-title":"Severe deformity in long-term Kaschin-Beck disease","volume":"61","author":"Shao","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026062507251508000_14.6.e014726.49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026062507251508000_14.6.e014726.50","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026062507251508000_14.6.e014726.51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:25:32Z","timestamp":1782397532000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2025-014726"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014726","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}